While biochemical alterations, such as the release of CGRP, PACAP, and VIP, have been well-documented in the pathophysiology of both CH and MH, these findings have also driven the development of novel therapeutic targets. This evidence concerns the gene ADCYAP1 and cyclic hematopoiesis.